002437 誉衡药业
已收盘 07-28 15:00:00
资讯
新帖
简况
单抗概念盘中拉升,誉衡药业涨停
市场透视 · 07-25
单抗概念盘中拉升,誉衡药业涨停
异动快报:誉衡药业(002437)7月25日9点32分触及涨停板
证券之星 · 07-25
异动快报:誉衡药业(002437)7月25日9点32分触及涨停板
黑龙江自贸区概念盘中拉升,誉衡药业涨4.42%
市场透视 · 07-24
黑龙江自贸区概念盘中拉升,誉衡药业涨4.42%
誉衡药业:与公司2022年之前原控股股东债务压力有关
证券之星 · 07-17
誉衡药业:与公司2022年之前原控股股东债务压力有关
誉衡药业:注射用多种维生素(12)销量增长40%
证券之星 · 07-17
誉衡药业:注射用多种维生素(12)销量增长40%
誉衡药业:7月16日接受机构调研,北京星樾管理咨询有限公司、金泰资本等多家机构参与
证券之星 · 07-17
誉衡药业:7月16日接受机构调研,北京星樾管理咨询有限公司、金泰资本等多家机构参与
誉衡药业:2025年半年度报告拟于2025年8月27日披露
证券之星 · 07-11
誉衡药业:2025年半年度报告拟于2025年8月27日披露
异动快报:誉衡药业(002437)7月10日9点59分触及涨停板
证券之星 · 07-10
异动快报:誉衡药业(002437)7月10日9点59分触及涨停板
誉衡药业:该产品目前在国内尚未开始销售
证券之星 · 07-10
誉衡药业:该产品目前在国内尚未开始销售
誉衡药业股价下跌2.40% 公司回应维生素产品市场占比超80%
金融界 · 07-09
誉衡药业股价下跌2.40% 公司回应维生素产品市场占比超80%
誉衡药业:7月1日高管刘月寅、王小航、李润宝减持股份合计143.46万股
证券之星 · 07-02
誉衡药业:7月1日高管刘月寅、王小航、李润宝减持股份合计143.46万股
互联网保险概念盘中跳水,誉衡药业跌1.06%
市场透视 · 06-30
互联网保险概念盘中跳水,誉衡药业跌1.06%
誉衡药业最新公告:普德药业注射用多种维生素(12)通过一致性评价
证券之星 · 06-24
誉衡药业最新公告:普德药业注射用多种维生素(12)通过一致性评价
每周股票复盘:誉衡药业(002437)一季度归母净利润增长15.24%
证券之星 · 06-13
每周股票复盘:誉衡药业(002437)一季度归母净利润增长15.24%
誉衡药业:6月11日接受机构调研,信达证券、大成基金等多家机构参与
证券之星 · 06-11
誉衡药业:6月11日接受机构调研,信达证券、大成基金等多家机构参与
异动快报:誉衡药业(002437)6月9日10点18分触及涨停板
证券之星 · 06-09
异动快报:誉衡药业(002437)6月9日10点18分触及涨停板
每周股票复盘:誉衡药业(002437)获甲钴胺注射液独家推广权
证券之星 · 06-06
每周股票复盘:誉衡药业(002437)获甲钴胺注射液独家推广权
誉衡药业(002437.SZ)下属与卫材中国药业就甲钴胺注射液签订市场推广服务协议
智通财经 · 06-03
誉衡药业(002437.SZ)下属与卫材中国药业就甲钴胺注射液签订市场推广服务协议
每周股票复盘:誉衡药业(002437)高管计划减持股份
证券之星 · 05-30
每周股票复盘:誉衡药业(002437)高管计划减持股份
【誉衡药业:三高管拟合计减持0.0639%公司股份】誉衡药业公告,副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内,通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股,各占公司总股本的0.0262%;刘月寅拟减持25.96万股,占公司总股本的0.0116%。减持原因是个人资金需求,减持价格将按市场价格确定。
金融界 · 05-29
【誉衡药业:三高管拟合计减持0.0639%公司股份】誉衡药业公告,副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内,通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股,各占公司总股本的0.0262%;刘月寅拟减持25.96万股,占公司总股本的0.0116%。减持原因是个人资金需求,减持价格将按市场价格确定。
加载更多
公司概况
公司名称:
哈尔滨誉衡药业股份有限公司
所属行业:
医药制造业
上市日期:
2010-06-23
主营业务:
哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是鹿瓜多肽注射液、安脑丸、安脑片、氯化钾缓释片、注射用磷酸肌酸钠、银杏达莫注射液、注射用多种维生素(12)、注射用氟尿嘧啶、注射用盐酸平阳霉素。报告期内,公司品牌价值和行业认可度继续提升,公司荣获“米内网”颁发的“2023年度中国化药企业TOP100”。
发行价格:
50.00
{"stockData":{"symbol":"002437","market":"SZ","secType":"STK","nameCN":"誉衡药业","latestPrice":3.4,"timestamp":1753686216000,"preClose":3.41,"halted":0,"volume":304971891,"delay":0,"changeRate":-0.0029,"floatShares":2101000000,"shares":2246000000,"eps":0.1072,"marketStatus":"已收盘","change":-0.01,"latestTime":"07-28 15:00:00","open":3.36,"high":3.51,"low":3.36,"amount":1047000000,"amplitude":0.044,"askPrice":3.41,"askSize":7573,"bidPrice":3.4,"bidSize":23563,"shortable":0,"etf":0,"ttmEps":0.1072,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753752600000},"marketStatusCode":5,"adr":0,"adjPreClose":3.41,"symbolType":"stock","openAndCloseTimeList":[[1753666200000,1753673400000],[1753678800000,1753686000000]],"highLimit":3.75,"lowLimit":3.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2245789726,"isCdr":false,"pbRate":3.96,"roa":"--","peRate":31.716418,"roe":"3.08%","epsLYR":0.1059,"committee":0.470466,"marketValue":7636000000,"turnoverRate":0.1451,"status":1,"floatMarketCap":7145000000},"requestUrl":"/m/hq/s/002437","defaultTab":"news","newsList":[{"id":"2554734415","title":"单抗概念盘中拉升,誉衡药业涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554734415?lang=zh_cn&edition=full","pubTime":"2025-07-25 09:37","pubTimestamp":1753407453,"startTime":"0","endTime":"0","summary":"07月25日,单抗概念盘中拉升,截至09点37分,单抗概念整体指数上涨0.66%,报2690.320点。从个股上来看,该概念的成分股中,誉衡药业涨停,百济神州-U、华海药业、华东医药涨幅居前。从资金上来看,截止发稿,单抗概念概念主力净流入为-4863.45万,其中誉衡药业受到资金热捧,主力净流入1.18亿;拉长时间线来看,该板块近20日主力资金净流入-4.73亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725093733971d2e99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725093733971d2e99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0060","BK0070","BK0239","002437","BK0185","BK0012","600521","BK0095","BK0201","BK0188","688235","BK0077"],"gpt_icon":0},{"id":"2554734796","title":"异动快报:誉衡药业(002437)7月25日9点32分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734796","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554734796?lang=zh_cn&edition=full","pubTime":"2025-07-25 09:36","pubTimestamp":1753407400,"startTime":"0","endTime":"0","summary":"证券之星7月25日盘中消息,9点32分誉衡药业触及涨停板。目前价格3.6,上涨10.09%。其所属行业化学制药目前上涨。领涨股为康芝药业。该股为医药,维生素,中药概念热股,当日医药概念上涨0.17%,维生素概念上涨0.12%,中药概念上涨0.07%。7月24日的资金流向数据方面,主力资金净流入1434.86万元,占总成交额2.53%,游资资金净流出838.98万元,占总成交额1.48%,散户资金净流出595.88万元,占总成交额1.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072500008989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","002437","BK0028","BK0239","BK0077","BK0095"],"gpt_icon":0},{"id":"2553942224","title":"黑龙江自贸区概念盘中拉升,誉衡药业涨4.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553942224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553942224?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:36","pubTimestamp":1753320961,"startTime":"0","endTime":"0","summary":"07月24日,黑龙江自贸区概念盘中拉升,截至09点35分,黑龙江自贸区概念整体指数上涨0.56%,报1301.250点。从个股上来看,该概念的成分股中,誉衡药业涨4.42%,哈三联、珍宝岛、新光光电涨幅居前。从资金上来看,截止发稿,黑龙江自贸区概念主力净流入为2461.07万,其中佳电股份受到资金热捧,主力净流入2623.80万;拉长时间线来看,该板块近20日主力资金净流入-38.37亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724093601a4601b98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724093601a4601b98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0188","BK0214","BK0060","688011","002437","BK0095","BK0077","BK0028"],"gpt_icon":0},{"id":"2552104442","title":"誉衡药业:与公司2022年之前原控股股东债务压力有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2552104442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552104442?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:30","pubTimestamp":1752741041,"startTime":"0","endTime":"0","summary":"证券之星消息,誉衡药业(002437)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问:很少能看到贵司近几年的券商研报,公司了解过吗,什么原因?誉衡药业回复:您好!一方面与公司2022年之前原控股股东债务压力有关;另一方面今年市场关注的重点为创新药。仅供参考。谢谢~以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700025183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0095","002437","BK0188","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2552044041","title":"誉衡药业:注射用多种维生素(12)销量增长40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552044041","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552044041?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:30","pubTimestamp":1752741041,"startTime":"0","endTime":"0","summary":"证券之星消息,誉衡药业07月17日在投资者关系平台上答复投资者关心的问题。注射用多种维生素为公司维矿领域核心产品,该产品已在河南十九省联盟集采、浙江第四批集采、河北牵头的京津冀赣化学药品集采、江苏省第五轮药品集采中中选,2024年,注射用多种维生素销量增长40%,2025年的销量有望延续增长趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700025184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0239","002437","BK0077","BK0188","BK0028","BK0060"],"gpt_icon":0},{"id":"2552017489","title":"誉衡药业:7月16日接受机构调研,北京星樾管理咨询有限公司、金泰资本等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2552017489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552017489?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:32","pubTimestamp":1752715961,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年7月16日誉衡药业发布公告称公司于2025年7月16日接受机构调研,北京星樾管理咨询有限公司、金泰资本、上海证券、中投万方(北京)投资基金管理有限公司、中财招商投资集团有限公司、北京宝湖投资管理有限公司、魏先生参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700006997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","002437","BK0028","BK0095","BK0077"],"gpt_icon":0},{"id":"2550594980","title":"誉衡药业:2025年半年度报告拟于2025年8月27日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2550594980","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550594980?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:39","pubTimestamp":1752223164,"startTime":"0","endTime":"0","summary":"证券之星消息,誉衡药业(002437)07月11日在投资者关系平台上答复投资者关心的问题。投资者提问:中报几号公布?誉衡药业回复:您好!公司2025年半年度报告拟于2025年8月27日披露,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071100026304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437","BK0188","BK0077","BK0095","BK0060","BK0028","BK0239"],"gpt_icon":0},{"id":"2550698751","title":"异动快报:誉衡药业(002437)7月10日9点59分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2550698751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550698751?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:00","pubTimestamp":1752112858,"startTime":"0","endTime":"0","summary":"证券之星7月10日盘中消息,9点59分誉衡药业触及涨停板。目前价格3.14,上涨10.18%。其所属行业化学制药目前上涨。领涨股为联环药业。该股为PD-1抑制剂,医药,中药概念热股,当日PD-1抑制剂概念上涨1.74%,医药概念上涨0.79%,中药概念上涨0.65%。7月9日的资金流向数据方面,主力资金净流出4442.94万元,占总成交额14.96%,游资资金净流入472.15万元,占总成交额1.59%,散户资金净流入3970.78万元,占总成交额13.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000009201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0028","BK0239","002437","BK0077","BK0095"],"gpt_icon":0},{"id":"2550666735","title":"誉衡药业:该产品目前在国内尚未开始销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550666735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550666735?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:06","pubTimestamp":1752109564,"startTime":"0","endTime":"0","summary":"证券之星消息,誉衡药业(002437)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司代理的佩玛贝特开始出货了没?什么时候能在市面上买到?誉衡药业回复:您好!该产品目前在国内尚未开始销售,预计今年9月份后销售。公司正在积极推进相关工作,感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000006082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0188","002437","BK0060","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2550148650","title":"誉衡药业股价下跌2.40% 公司回应维生素产品市场占比超80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550148650","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550148650?lang=zh_cn&edition=full","pubTime":"2025-07-10 02:43","pubTimestamp":1752086622,"startTime":"0","endTime":"0","summary":"截至2025年7月9日15时,誉衡药业股价报2.85元,较前一交易日下跌0.07元,跌幅2.40%。誉衡药业属于化学制药板块,公司核心业务涵盖药品研发、生产和销售,主要产品包括注射用多种维生素等。该产品在同类市场中占据80%以上的份额,竞争格局较为稳定。7月9日,誉衡药业接待了首创证券的调研,公司高管就维生素类产品的市场表现及未来销售预期作出回应。数据显示,近一年来誉衡药业共接受86家机构108次调研。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10024351596096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0095","BK0060","BK0077","BK0028","002437","BK0188","BK0239"],"gpt_icon":0},{"id":"2548891717","title":"誉衡药业:7月1日高管刘月寅、王小航、李润宝减持股份合计143.46万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548891717","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548891717?lang=zh_cn&edition=full","pubTime":"2025-07-02 20:01","pubTimestamp":1751457706,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月2日市场公开信息、上市公司公告及交易所披露数据整理,誉衡药业最新董监高及相关人员股份变动情况:2025年7月1日公司董事,副总经理,董事会秘书刘月寅、副总经理王小航、副总经理李润宝共减持公司股份143.46万股,占公司总股本为0.064%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200034293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002437","BK0095","BK0060","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2547311190","title":"互联网保险概念盘中跳水,誉衡药业跌1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2547311190","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547311190?lang=zh_cn&edition=full","pubTime":"2025-06-30 09:44","pubTimestamp":1751247842,"startTime":"0","endTime":"0","summary":"06月30日,互联网保险概念盘中跳水,截至09点43分,互联网保险概念整体指数下跌0.53%,报1915.960点。从个股上来看,该概念的成分股中,誉衡药业跌1.06%,金证股份、新华保险、东方财富跌幅居前。从资金上来看,截止发稿,互联网保险概念主力净流入为-3.62亿,其中XD中国平受到资金热捧,主力净流入3099.59万;拉长时间线来看,该板块近20日主力资金净流入9.08亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300944029530a299&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506300944029530a299&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1979443071.USD","160636","LU1580142542.USD","BK0060","LU1146622755.USD","LU0051755006.USD","LU2328871848.SGD","LU1655091616.SGD","LU1781817850.SGD","LU1969619763.USD","BK0239","BK0032","LU2289578879.USD","BK0187","BK0188","SG9999002463.SGD","BK0070","159792","BK0095","LU0405327148.USD","LU0405327494.USD","BK0077","LU0456827905.SGD","LU2213484517.USD","LU1064131003.USD","LU1820825898.SGD","LU2148510915.USD","LU0047713382.USD","LU1997244956.HKD","BK0012","LU1997245094.SGD","LU2495084118.USD","LU0039217434.USD","BK0196","LU1934453819.USD","BK0183","601318","BK0207","LU1997245177.USD","BK0028","LU0326950275.SGD","LU0456846285.SGD","IE0005HP3H50.USD","LU1064130708.USD","BK0175","002437"],"gpt_icon":0},{"id":"2545283213","title":"誉衡药业最新公告:普德药业注射用多种维生素(12)通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2545283213","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545283213?lang=zh_cn&edition=full","pubTime":"2025-06-24 18:00","pubTimestamp":1750759229,"startTime":"0","endTime":"0","summary":"誉衡药业(002437.SZ)公告称,6月24日,公司全资下属公司山西普德药业有限公司(简称“普德药业”)收到国家药监局核准签发的注射用多种维生素(12)《药品补充申请批准通知书》,该药品通过了仿制药质量和疗效一致性评价。注射用多种维生素(12)为静脉补充维生素用药,适用于当口服营养禁忌、不能或不足(营养不良、吸收不良、胃肠外营养……),需要通过注射补充维生素的成人及11岁以上儿童患者。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400029610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","002437","BK0188","BK0239","BK0095","BK0028"],"gpt_icon":0},{"id":"2543634293","title":"每周股票复盘:誉衡药业(002437)一季度归母净利润增长15.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543634293","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543634293?lang=zh_cn&edition=full","pubTime":"2025-06-14 02:51","pubTimestamp":1749840690,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘,誉衡药业报收于2.99元,较上周的2.76元上涨8.33%。本周,誉衡药业6月10日盘中最高价报3.25元,股价触及近一年最高点。氯化钾缓释片已于 2024 年 4 月中标河南十三省联盟药品采购。截至2024年底,公司商誉为3.69亿元,是2015年度收购普德药业产生的。2025 年一季度,公司营业收入较去年同期下降 7.06%,归母净利润较去年同期增长 15.24%,预计今年营业收入将保持平稳或略微下降,经营业绩较去年继续实现增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400005325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437"],"gpt_icon":0},{"id":"2542825533","title":"誉衡药业:6月11日接受机构调研,信达证券、大成基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2542825533","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542825533?lang=zh_cn&edition=full","pubTime":"2025-06-11 22:31","pubTimestamp":1749652285,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年6月11日誉衡药业发布公告称公司于2025年6月11日接受机构调研,信达证券、大成基金、天治基金、嘉实基金、上海肇万资产、拾贝投资、天弘基金参与。氯化钾缓释片已于 2024 年 4 月中标河南十三省联盟药品采购。公司每年底会进行商誉减值测试,以目前普德药业的盈利水平、现金流等运营情况来看,不存在减值迹象。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061100037513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601059","BK0276","BK0188","BK0028","BK0239","BK0077","BK0095","BK0060","002437"],"gpt_icon":0},{"id":"2542759258","title":"异动快报:誉衡药业(002437)6月9日10点18分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2542759258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542759258?lang=zh_cn&edition=full","pubTime":"2025-06-09 10:20","pubTimestamp":1749435636,"startTime":"0","endTime":"0","summary":"证券之星6月9日盘中消息,10点18分誉衡药业触及涨停板。目前价格3.04,上涨10.14%。其所属行业化学制药目前上涨。领涨股为海辰药业。该股为PD-1抑制剂,医药,中药概念热股,当日PD-1抑制剂概念上涨3.41%,医药概念上涨3.07%,中药概念上涨2.55%。6月6日的资金流向数据方面,主力资金净流出3340.92万元,占总成交额11.06%,游资资金净流出14.5万元,占总成交额0.05%,散户资金净流入3355.42万元,占总成交额11.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900005187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0095","BK0028","BK0077","002437","BK0060"],"gpt_icon":0},{"id":"2541860345","title":"每周股票复盘:誉衡药业(002437)获甲钴胺注射液独家推广权","url":"https://stock-news.laohu8.com/highlight/detail?id=2541860345","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541860345?lang=zh_cn&edition=full","pubTime":"2025-06-07 03:07","pubTimestamp":1749236831,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘,誉衡药业报收于2.76元,较上周的2.92元下跌5.48%。本周关注点公司公告汇总: 誉衡药业全资下属公司获得甲钴胺注射液中国大陆地区独家推广权公司公告汇总誉衡药业全资下属公司天津誉衡博达科技有限公司与卫材(中国)药业有限公司签订了关于甲钴胺注射液的《市场推广服务协议》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700004571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0095","BK0239","BK0028","BK0188","002437","BK0077"],"gpt_icon":0},{"id":"2540726318","title":"誉衡药业(002437.SZ)下属与卫材中国药业就甲钴胺注射液签订市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2540726318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540726318?lang=zh_cn&edition=full","pubTime":"2025-06-03 16:35","pubTimestamp":1748939746,"startTime":"0","endTime":"0","summary":"智通财经APP讯,誉衡药业 公告,公司全资下属公司天津誉衡博达科技有限公司与卫材(中国)药业有限公司就“甲钴胺注射液”签订《市场推广服务协议》。根据协议,卫材中国药业授权天津博达在中国大陆地区独家推广甲钴胺注射液,授权期限自2025年6月1日起至协议有效期届满之日终止。天津博达负责提供该产品在上述区域的市场推广服务和其他相关服务。卫材中国药业将按照协议约定向天津博达支付相应的市场推广服务费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK0239","BK0077","BK0095","BK0060","002437"],"gpt_icon":0},{"id":"2539373274","title":"每周股票复盘:誉衡药业(002437)高管计划减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2539373274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539373274?lang=zh_cn&edition=full","pubTime":"2025-05-31 01:35","pubTimestamp":1748626539,"startTime":"0","endTime":"0","summary":"截至2025年5月30日收盘,誉衡药业报收于2.92元,较上周的2.68元上涨8.96%。本周,誉衡药业5月29日盘中最高价报3.11元,股价触及近一年最高点。誉衡药业当前最新总市值65.58亿元,在化学制药板块市值排名73/150,在两市A股市值排名2300/5146。本周关注点公司公告汇总:誉衡药业部分董事及高级管理人员计划减持公司股份公司公告汇总誉衡药业部分董事及高级管理人员计划减持公司股份。减持价格将按照市场价格确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053100003098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","002437","BK0028","BK0095","BK0077"],"gpt_icon":0},{"id":"2539125763","title":"【誉衡药业:三高管拟合计减持0.0639%公司股份】誉衡药业公告,副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内,通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股,各占公司总股本的0.0262%;刘月寅拟减持25.96万股,占公司总股本的0.0116%。减持原因是个人资金需求,减持价格将按市场价格确定。","url":"https://stock-news.laohu8.com/highlight/detail?id=2539125763","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539125763?lang=zh_cn&edition=full","pubTime":"2025-05-29 19:41","pubTimestamp":1748518890,"startTime":"0","endTime":"0","summary":"誉衡药业公告,副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计划自公告披露之日起15个交易日后的三个月内,通过集中竞价方式减持公司股份。李润宝和王小航分别拟减持58.75万股,各占公司总股本的0.0262%;刘月寅拟减持25.96万股,占公司总股本的0.0116%。减持原因是个人资金需求,减持价格将按市场价格确定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/29194150747748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0095","BK0188","002437","BK0060","BK0028","BK0077","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753726531155,"stockEarnings":[{"period":"1week","weight":0.0429},{"period":"1month","weight":0.1972},{"period":"3month","weight":0.371},{"period":"6month","weight":0.3655},{"period":"1year","weight":0.8681},{"period":"ytd","weight":0.3655}],"compareEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":0.0507},{"period":"3month","weight":0.0947},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0734}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"哈尔滨誉衡药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114200人(较上一季度增加13.18%)","perCapita":"18400股","listingDate":"2010-06-23","address":"黑龙江省哈尔滨市呼兰区利民经济技术开发区北京路29号","registeredCapital":"224578万元","survey":" 哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是鹿瓜多肽注射液、安脑丸、安脑片、氯化钾缓释片、注射用磷酸肌酸钠、银杏达莫注射液、注射用多种维生素(12)、注射用氟尿嘧啶、注射用盐酸平阳霉素。报告期内,公司品牌价值和行业认可度继续提升,公司荣获“米内网”颁发的“2023年度中国化药企业TOP100”。","listedPrice":50},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"誉衡药业,002437,誉衡药业股票,誉衡药业股票老虎,誉衡药业股票老虎国际,誉衡药业行情,誉衡药业股票行情,誉衡药业股价,誉衡药业股市,誉衡药业股票价格,誉衡药业股票交易,誉衡药业股票购买,誉衡药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}